Emeis Stock Falls by 3.44% to €14.61 Despite a Yearly Gain of 32.77%
The Emeis stock has fallen by 3.44% to €14.61 at midday on this Monday, May 11, 2026, within a SBF 120 that is down by 0.85%. The stock is among the top ten declines of the index, following a week marked by the release of a strong quarterly revenue figure. However, it still maintains a yearly gain of 32.77%.
Emeis is ranked 117th in the SBF 120 for the session, among the most significant drops in the broad index. This movement comes a few days after the publication of the first quarter revenue, which showed an organic growth of 6.3% and confirmed the EBITDAR guidance for 2026 (growth exceeding 10%). The session is generally unfavorable for European stocks, with the CAC 40 down by 0.96% amid ongoing tensions in the Middle East and rising Brent prices above $103. Nevertheless, the stock is still up by 1.95% for the week and 32.77% over twelve months, reflecting the recovery trajectory of the group of retirement homes and clinics initiated since 2024.
Price Still Above Its Moving Averages
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Despite today's decline, the price at €14.61 remains above its three moving averages: MM20 at €14.24, MM50 at €14.03, and MM200 at €13.70. The RSI at 62 indicates a buying momentum still present, without excess. The stock is trading in the upper part of the Bollinger Bands (66%), with an upper limit at €15.43, which is close to the resistance identified at €15.29. According to TP Icap Midcap, the target price set at €17 in a recent note offers a theoretical potential of over 16% compared to today's price. The appointment of Jean-Marc Boursier as Deputy CEO, effective July 1, 2026, remains an upcoming milestone in governance. The technical support is located at €12.26.
SectorServices et infrastructure de santé›Etablissements de santé / EHPAD
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3 011 millions d'euros
Quarterly revenue: 3 011 millions d'euros
EBITDA: 461 millions d'euros
EBITDA margin: 15,3 %
Net income: -40,4 millions d'euros
Free cash flow: -153 millions d'euros
3 862 millions d'euros
Guidance from the release
First-half performance allows for an upward revision of the 2026 guidance; the trend since the start of the year confirms the continued momentum observed in 2025 and even shows performance that exceeded the Group's initial expectations
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
